RMD ResMed Inc.

ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021

ResMed to Report Third Quarter Fiscal 2021 Earnings on April 29, 2021

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

Earnings webcast details:

    • Location:    
    • Date:   Thursday, April 29, 2021
    • Time:    1:30 p.m. PDT / 4:30 p.m. EDT
    • International: London, Thursday, April 29, 9:30 p.m. BST
  Sydney, Friday, April 30, 6:30 a.m. AEST

Please note that ResMed does not use outside phone lines to access the earnings call.



A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from April 29 until May 13 at:

  • U.S.: +1 800.585.8367
  • International: +1 416.621.4642
  • Conference ID: 7757454

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit and follow @ResMed.

For investors                                                

Amy Wakeham                                                

+1 858.836.5000                                                

    
 For media

Jayme Rubenstein

+1 858.836.6798

 


EN
08/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis 36,000 people across 17 markets responded to the company’s fourth annual survey.40% of respondents get no more than three nights of good sleep per week.More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality. SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and othe...

 PRESS RELEASE

Introducing the AirFit F40: Experience Unprecedented Freedom with the ...

Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask.Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night. 96% of patients using the AirFit F40 said they have the freedom to sleep in their preferred positio...

ResMed Inc: 1 director

A director at ResMed Inc sold 23,535 shares at 182.664USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers ...

ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapyPart of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: ...

 PRESS RELEASE

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 20...

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024 Year-over-year revenue grows 12%, operating profit down 2%, non-GAAP operating profit up 20%Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023. Second Quarter 2024 HighlightsAll comparisons are to the prior year period Revenue increased by 12% to $1.2 billion; up 1...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch